CONTENTS

SECTION 1 NEHODS- Northern England Haemato- Diagnostic Service

SECTION 2 Guidelines for Cytogenetic analysis in Haematological Malignancies

SECTION 3 North of England Cancer Network Guidelines and Indications for PETCT

SECTION 4 Guidelines for management of Acute Myeloid Leukaemia (AML)

SECTION 5 Guidelines for Management of Myelodysplastic Syndromes

SECTION 6 Guidelines for Management of Acute Lymphoblastic Leukaemia

SECTION 7 Guidelines for the Management of Chronic Myeloid Leukaemia

SECTION 8 Guidelines for Management of Myeloproliferative Disorders
  Polycythaemia Vera (PRV)
  Myelofibrosis (MF)

SECTION 9 Guidelines for Management of Chronic Lymphocytic Leukaemia (CLL) and Lymphoproliferative Disorders
  Hairy Cell Leukaemia
  T-Prolymphocytic Leukaemia
  Waldenstrom Macroglobulinaemia

SECTION 10 Guidelines for the Management of Low-grade Non-Hodgkin Lymphoma
  Mantle Cell Lymphoma

SECTION 11 Guidelines for the Management of High Grade B Cell Non-Hodgkin Lymphoma (NHL)

SECTION 12 Guidelines for the Management of Classical Hodgkin Lymphoma

SECTION 13 Guidelines for the Management of Mature T-Cell and NK-Cell Neoplasms

SECTION 14 Guidelines for Management of Plasma Cell Myeloma

SECTION 15 Indications for Haemopoietic Stem Cell Transplantation

SECTION 16 Clinical Guideline for the prophylaxis and treatment of tumour lysis syndrome in patients receiving treatment for haematological malignancies

SECTION 17 Blood Transfusion Guidelines

SECTION Appendix
  Appendix 1 – Teenage and Young Adult Pathway for initial Management
  Appendix 2 – Pathway for follow up on completion of First line treatment
  Appendix 3- TYA Designated Hospitals
  Appendix 4 – NHS Specialised Services Pathway
  Appendix 5 – Local Referral Pathways and Levels of Care
  Appendix 6 - Pathways
  Appendix 7 – Inter-provider transfers
    • Multiple Myeloma
    • Non-Hodgkin Lymphoma
    • Hodgkin Lymphoma
GUIDELINES FOR MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA

Overview

The Alliance Expert Advisory Group recommends that all adult patients with acute lymphoblastic leukaemia (precursor B-lineage and T-lineage ALL) are invited for entry into the UKALL 14 trial if eligible.

The main inclusion criteria of UKALL14
1. age ≥ 25 and ≤ 65
2. newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days is acceptable and can be started prior to registration)

The main exclusion criteria of UKALL14
1. known HIV infection
2. pregnant or lactating women
3. blast transformation of chronic myelogenous leukaemia
4. mature B-cell leukemia i.e. Burkitt’s disease t(8,14)(q24;q32) and all disorders with amplification of c-myc e.g. t(2;8)(p12;q24),t(8;22)(q24;q11)

Patients of age between 18 and 24 must be referred to the Teenage and Young Adult MDT and should be considered to be entered into UKALL2011 study

For patients who are not entered into these trials, the following protocols are recommended as the standard of care.

- UKALL 2011 for 24 years and under (discuss at the Teenage and Young Adult MDT), and
- UKALL 14 “standard treatment” arms for adults of age ≥ 25 and ≤ 65
- UKALL60 for adults >60 if unfit for UKALL14 study – treatment pathways are dependent on cytogenetics, co-morbidities and performance status

NHS England has nationally approved PEG-asparaginase instead of L-asparaginase for induction ALL therapy

1. Adults 16-24 years - UKALL2011 trial

Refer to UKALL2011 for guidance on treatment schedules, supportive care and details of MRD testing.


All patients aged > 10 are classified as NCI high risk and will receive regimen B.
MRD monitoring is done at day 29 and further treatment is stratified based on MRD results at day 29 or tumour volume if LBL. Patients with MRD risk (>0.005%) and MRD No results but slow early responder on day 8 marrow will be switched to regimen C.

Allogenic transplantation is not recommended in patients with CR1 independent of cytogenetics.

2. Adults 25-60 years as well as adults >60 fit enough to be considered for an allograft - UKALL14 trial

It is recommended to refer to the UKALL 14 protocol for treatment schedules MRD testing and supportive care.

- Patients who are not entered into the UKALL14 trial, should receive treatment according to the “standard” arms of the UKALL 14 protocol.
- See the treatment algorithm for adults with acute lymphoblastic leukaemia : age ≥ 24 years. (UKALLL 14 standard treatment arm).
- Refer to the UKALL 14 protocol for details of phase 1 induction; phase 2 induction, intensification, consolidation and maintenance therapy.
- Patients with Philadelphia positive disease (Ph+ ALL) should also receive continuous daily imatinib, orally, starting at 400mg daily, aiming to escalate to 600mg daily within 2 weeks, if tolerated. This should be continued until transplant wherever possible.
- Important: Patients with Philadelphia positive ALL should not receive PEG-asparaginase at any timepoint.
- Patients who achieve complete remission have risk assessment at the end of phase 2 of induction. Any one of the factors below makes the patient high-risk.

1. Age over 40 years
2. WBC ≥30 x 10^9/L (precursor-B), ≥100 x 10^9/L (T-lineage)
3. Cytogenetics – any one or more of the abnormalities below
   - t(4;11)(q21;q23)/MLL-AF4
   - low hypodiploidy/near triploidy (30-39 chromosomes / 60-78 chromosomes)
   - complex karyotype (five or more chromosomal abnormalities)
   - Philadelphia chromosome t(9;22) (q34;q11)/BCR-ABL1 (detected by cytogenetic or molecular methods)
4. High Risk Minimal Residual Disease (MRD) post phase 2 of induction.

- If the MRD result is not available (failed or specimen not sent) patient should be considered standard risk in the absence of any other high risk features.

TREATMENT ALGORITHM FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA : Age ≥ 24 years. (UKALL 14 Standard Treatment Arm)
Refer to the UKALL 14 protocol for details.
Steroid pre-phase (5-7 days); dexamethasone 6 mg/m²/day orally for 5-7 days

Phase 1 induction (4 weeks): pegylated asparaginase (PEG-ASP) + standard phase 1 induction therapy

Phase 2 induction (4 weeks): standard phase 2 induction therapy

Patients in complete remission: risk assessment performed on all patients at this point.

- **YES**
  - Sibling donor present

- **NO**
  - Over 40 years old
    - Intensification with high-dose methotrexate + PEG-ASP
    - Conditioning regimen with fludarabine + melphalan + alemtuzumab
    - Allo-SCT (sibling)

- **Over 40 years old**
  - Myeloablative conditioning regimen (e.g. etoposide) + TBI
  - Allo-SCT (sibling)

- **40 years old and under**
  - Conditioning regimen with fludarabine + melphalan + alemtuzumab
  - Allo-SCT (MUD)

- **HIGH RISK**
  - Over 40 years old
    - Intensification with high-dose methotrexate + PEG-ASP
  - Myeloablative conditioning regimen (e.g. etoposide) + TBI
  - Allo-SCT (MUD)

- **STANDARD RISK**
  - Continue methotrexate intensification, consolidation and maintenance
SCHEDULE OF TESTING FOR MINIMAL RESIDUAL DISEASE (MRD) FOR RISK ASSESSMENT

<table>
<thead>
<tr>
<th>Specimens for local assessment</th>
<th>Specimens to be sent to central laboratory**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At Diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>Cytogenetics/molecular assessment of BCR-ABL and MLL on bone marrow.</td>
<td>Bone marrow 3-5ml in EDTA (OR peripheral blood 30-50ml in EDTA if WCC &gt; 30 × 10^9/L). BCR-ABL status will also be checked.</td>
</tr>
<tr>
<td><em><em>At recovery</em> post Phase 1</em>*</td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate for remission assessment locally.</td>
<td>Bone marrow from biopsy: 3-5ml in EDTA for MRD assessment (IgH/TCR rearrangements for Ph-ALL, BCR-ABL for Ph+ALL)</td>
</tr>
<tr>
<td><em><em>At recovery</em> post Phase 2</em>*</td>
<td></td>
</tr>
<tr>
<td>Bone marrow aspirate for remission assessment locally.</td>
<td>Bone marrow from biopsy: 3-5ml in EDTA for MRD assessment (IgH/TCR rearrangements for Ph-ALL, BCR-ABL for Ph+ALL)</td>
</tr>
</tbody>
</table>

*Recovery is defined as neutrophils >0.75 × 10^9/L, platelets >75 × 10^9/L.

**All samples should be sent by courier or by 1st class post to arrive the same day or overnight to the following address:

Minimal Residual Disease Laboratory
URGENT UKALL14 STUDY SAMPLE (FAO Adele Fielding, Rachel Mitchell or Krisztina Alapi)
UCL Cancer Institute
Paul O’Gorman Building
72 Huntley Street
London UK
WC1E 6DD

MRD Lab email: ALLMRDlab@ucl.ac.uk

**Adults > 60 years - UKALL60 trial**

It is recommended to refer to the UKALL60 protocol for treatment schedules and supportive care.

UKALL60 Protocol
Latest Resources/Other

Four different treatment pathways are suggested depending on cytogenetics, co-morbidities and performance status of patient. The treatment pathway will be chosen by local clinician after discussion with patient.
1.2 Study Schema

Informed consent & registration

Treatment Allocation/Choice*

PH +ve

PHILADELPHIA POSITIVE

PHILADELPHIA NEGATIVE (INTENSIVE)

PHILADELPHIA NEGATIVE (INTENSIVE+)

PHILADELPHIA NEGATIVE (NON-INTENSIVE)

Induction Phase 1

Induction Phase 2

Intensification

Consolidation 1

Consolidation 2

Consolidation 2

Consolidation 3

Maintenance (2 years)

FOLLOW UP: Patients to be followed up annually from completion of maintenance for 5 years

PH -ve

Diagnostic bone marrow*

*Treatment pathway to be chosen by local investigator after consultation with patient and taking into account performance status, co-morbidities and personal preference. Reason for choice will be documented.

DATA COLLECTION ONLY

Registration only

*Bone marrow samples sent to central lab for MRD
All patients with Philadelphia positive ALL will be treated as per pathway A. Patients with Ph-neg ALL need to be carefully assessed and depending on clinical status can either be offered, an intensive arm (pathway B), an intensive + arm (pathway C) or a non-intensive arm (pathway D)

MRD assessment is experimental and should only be undertaken if patient is participating in the study. Intent is potentially curative but although remission is often achieved, relapses frequently occur and relapsing patients would not normally be offered salvage chemotherapy. This protocol can also be used for patients aged 60 or younger deemed unfit for standard arm of UKALL14.

4. Relapsed ALL

Patients treated on UKALL 2011 and UKALL14 and not transplanted owing to perceived ‘low risk’ may relapse. Other options for reinduction include FLAG-Ida, clofarabine (via CDF) and nelarabine (via CDF). Patients should proceed to transplantation if remission is achieved.